Vaccine protection against simian immunodeficiency virus infection. 1989

R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
New England Regional Primate Research Center, Harvard Medical School, Southborough, MA 01772.

Rhesus monkeys were immunized by multiple inoculations with purified, disrupted, noninfectious simian immunodeficiency virus (SIV) in adjuvant. Immunized monkeys developed anti-SIV antibodies detectable by whole-virus ELISA and by immunoblot reactivity; these antibodies had weak neutralizing activity. One week after the last immunization, monkeys were challenged with 200-1000 animal infectious doses of uncloned, live SIV. The same strain of SIV that was used for vaccination was also used for challenge. Anamnestic antibody responses and SIV recovery from peripheral blood were used to evaluate infection following the live virus challenge; two of six vaccinated monkeys showed no evidence of infection following the live virus challenge. Transfusion of 10 ml of whole blood from these two into uninfected, naive rhesus monkeys did not result infection of the recipients, providing further support for the lack of infection in the two previously vaccinated animals. Four of four unvaccinated control monkeys inoculated with these doses of live SIV became infected and three of these died with AIDS 118-258 days after infection. Only one of the six vaccinated monkeys has died to date. In situ hybridization with lymph node biopsy specimens suggested that the virus load was much higher in control macaques than in vaccinated macaques. These results indicate that vaccination with inactivated whole virus can protect macaques against challenge with live SIV. Furthermore, they provide hope that vaccine protection against human AIDS virus infection may be possible.

UI MeSH Term Description Entries
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000914 Antibodies, Viral Immunoglobulins produced in response to VIRAL ANTIGENS. Viral Antibodies
D000917 Antibody Formation The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS. Antibody Production,Antibody Response,Antibody Responses,Formation, Antibody,Production, Antibody,Response, Antibody,Responses, Antibody
D012192 Retroviridae Infections Virus diseases caused by the RETROVIRIDAE. Retrovirus Infections,Infections, Retroviridae,Infections, Retrovirus,XMRV Infection,Xenotropic MuLV-related Virus Infection,Xenotropic Murine Leukemia Virus-related Virus Infection,Infection, Retroviridae,Infection, Retrovirus,Infection, XMRV,Infections, XMRV,Retroviridae Infection,Retrovirus Infection,XMRV Infections,Xenotropic MuLV related Virus Infection,Xenotropic Murine Leukemia Virus related Virus Infection
D014611 Vaccination Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. Immunization, Active,Active Immunization,Active Immunizations,Immunizations, Active,Vaccinations
D014765 Viral Vaccines Suspensions of attenuated or killed viruses administered for the prevention or treatment of infectious viral disease. Viral Vaccine,Vaccine, Viral,Vaccines, Viral
D015302 Simian Immunodeficiency Virus Species of the genus LENTIVIRUS, subgenus primate immunodeficiency viruses (IMMUNODEFICIENCY VIRUSES, PRIMATE), that induces acquired immunodeficiency syndrome in monkeys and apes (SAIDS). The genetic organization of SIV is virtually identical to HIV. SIV (Simian immunodeficiency virus),Immunodeficiency Viruses, Simian,Simian Immunodeficiency Viruses,Immunodeficiency Virus, Simian

Related Publications

R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
November 1990, AIDS research and human retroviruses,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
May 2002, Vaccine,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
May 2008, Current opinion in HIV and AIDS,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
September 2000, Journal of virology,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
December 2011, Journal of virology,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
August 2007, Australian veterinary journal,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
April 2002, Journal of virology,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
January 2000, Developments in biologicals,
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
January 2002, Journal of immunology (Baltimore, Md. : 1950),
R C Desrosiers, and M S Wyand, and T Kodama, and D J Ringler, and L O Arthur, and P K Sehgal, and N L Letvin, and N W King, and M D Daniel
April 2015, Journal of virology,
Copied contents to your clipboard!